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Abstract
Systemic hypertension is a major public health problem, nearly affecting 
one-third of the global adult population. It is the leading modifiable risk factor 
for coronary heart disease (CHD), cerebrovascular disease, renal dysfunction, 
peripheral arterial disease (PAD), heart failure and atrial fibrillation. Human 
brain is one of the most important target organs for hypertension related end-
organ damage. Two major categories of hypertension related cerebral diseases 
include stroke and dementia, which are associated with considerable morbidity 
and mortality. Large body of clinical evidence has shown that adequate control 
of elevated blood pressures (BPs) could be a very effective tool in reducing the 
incidence and prevalence of cerebrovascular diseases. In the following sections, we 
discuss the role of hypertension in the causation of cerebrovascular disease along 
with the preventive and therapeutic strategies for the same.
Keywords: cerebrovascular disease, stroke, dementia, blood pressure, hypertension, 
intracranial hemorrhage, management, brain, cerebral, ischemic
1. Introduction
Systemic hypertension is one of the most common and devastating disorders 
affecting the human race. It is a major cause of premature death worldwide and is 
the risk factor with greatest impact on the global burden of disease. It is the leading 
modifiable risk factor for cardiovascular disease and all-cause mortality [1, 2].
Worldwide, an estimated 1.38 billion individuals (31.1% of the adult popula-
tion) have hypertension, defined as systolic blood pressure (BP) ≥ 140 mm Hg 
and/or diastolic BP ≥ 90 mm Hg, and/or current use of antihypertensive medica-
tion. The age-standardized prevalence of hypertension is marginally higher in men 
(31.9%) than in women (30.1%) and is lower in high-income countries (HICs), 
as compared to low and middle-income countries (LMICs) (28.5% vs. 31.5%) [3]. 
According to global estimates in 2010, only 45.6% of individuals with hypertension 
were aware of the disease, only 36.9% were receiving treatment and only 13.8% 
had achieved adequate BP control (defined as systolic BP < 140 mm Hg and dia-
stolic BP < 90 mm Hg). Also, the proportion of hypertension awareness and treat-
ment was nearly twice and the proportion of hypertension control was four times 
in HICs as compared to LMICs. In the last 2 decades, HICs have shown substantial 
increases in the proportions of hypertension awareness, treatment and control. 
However, during the same period, awareness and treatment have increased only 
modestly in LMICs and the proportion of hypertensive patients having adequately 
controlled BP has decreased slightly [3].
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The global prevalence of hypertension is increasing steadily as a result of 
aging of the population and increase in lifestyle risk factors like unhealthy diets 
(high sodium, low potassium intake, high intake of saturated and trans-fats and 
low intake of fruits and vegetables), physical inactivity, increased consumption 
of alcohol and tobacco, and being overweight or obese. However, the changes in 
the prevalence of hypertension have not been uniform worldwide. In the last two 
decades, a modest decline has been noted in hypertension prevalence in HICs, 
whereas LMICs have experienced significant increases. These trends can impose a 
greater burden of hypertension and related cardiovascular disorders on the fragile 
health-care systems of LMICs, many of which are also facing a substantial burden 
of infectious diseases [4].
Hypertension is often called a “silent killer”, as most hypertensives are unaware 
of the problem due to lack of warning symptoms or signs. Hypertension can cause 
sub-clinical target organ damage for years, before any symptoms or signs develop. 
It is the leading modifiable risk factor implicated in the causation of coronary heart 
disease (CHD), cerebrovascular disease, renal dysfunction, peripheral arterial 
disease (PAD), heart failure and atrial fibrillation. The brain is a major target for 
hypertension related end-organ damage and hypertension is a prominent risk factor 
for two major categories of brain diseases: stroke and dementia. In the following 
sections, we discuss the role of hypertension in causation of these diseases, along 
with prevention and treatment strategies.
2. Hypertension and brain
Human brain, in general, is highly vulnerable to the harmful effects of elevated 
BP and it represents the classic target organ of hypertension-induced damage. 
Arterial hypertension, besides being responsible for its well-known effect in causing 
clinical stroke, is also associated with the development of asymptomatic, subclinical 
brain damage, such as cerebral small vessel disease with resultant cognitive impair-
ment, memory loss and dementia. Also, sudden and marked elevations of blood 
pressure can lead to the development of hypertensive encephalopathy, characterized 
by severe headache, seizures and other neurological symptoms like cerebral edema.
2.1 Hypertension and stroke
2.1.1 Hypertension as a risk factor for stroke
Globally, stroke ranks second among the causes of mortality and third among 
the causes of disability. In recent decades a trend towards reduction in the inci-
dence, prevalence and mortality of stroke has been noted, but the overall disease 
burden continues to rise in terms of total number of patients affected [5].
Stroke is usually categorized into ischemic and hemorrhagic forms. Ischemic 
stroke has further subtypes including large vessel occlusive disease, lacunar infarc-
tions due to small vessel disease, cerebral embolism including cardioembolic stroke, 
non-atherogenic stroke and cryptogenic stroke. Various subtypes of hemorrhagic 
stroke include intra-parenchymal hemorrhage, subarachnoid hemorrhage and 
intraventricular hemorrhage.
Hypertension is the most prevalent risk factor for stroke and has been reported 
in nearly two-thirds of stroke patients [6]. In LMICs, the reported prevalence of 
risk factors among patients with stroke is lower, however the in-hospital mortality 
rates have been higher, probably related to delays in presentation, differences in 
healthcare system responses and acute management of stroke [7].
3
Cerebrovascular Disease and Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.101180
There is robust evidence from observational and interventional studies, impli-
cating hypertension as a strong risk factor for all types of strokes. The Framingham 
heart study in 1970 showed a significant association between the risk of stroke and 
blood pressure ≥ 160/95 mm Hg at all ages and in both sexes [8]. Persons with a 
normal BP (<120/80 mm Hg) had been reported approximately half the lifetime 
risk of stroke compared to those with high BP (≥140/90 mm Hg) [9].
Large epidemiological studies have consistently shown the relationship between 
the level of BP and risk of stroke to be consistent, continuous, and independent 
of other risk factors. Older epidemiological studies gave more importance to the 
diastolic BP as a determinant of stroke risk, and consistently showed a higher risk 
of stroke with increasing levels of diastolic BP [10, 11]. MacMahon et al., in their 
meta-analysis of nine observational studies conducted between 1958 and 1990, 
showed that as the level of BP decreased so did the risk of stroke. A decrease in 
diastolic BP of 5, 7.5, and 10 mm Hg was associated with a lowering of stroke risk 
by 34, 46, and 56%, respectively [11]. Similarly, The Eastern Stroke and Coronary 
Heart Disease Collaborative Research project, showed that for every 5 mm Hg fall 
in the diastolic BP resulted in nearly 50% reduction in the risk of ischemic (odds 
ratio (OR) 0.61; 95% confidence interval 0.57–0.66) and hemorrhagic stroke (odds 
ratio 0.54, 95% confidence interval 0.50–0.58) [12]. Systolic BP attracted greater 
attention in 1990s after the results from many epidemiological studies suggested 
that it could have more robust association with stroke as compared to diastolic BP. 
Systolic BP also showed a stronger correlation with 12 year stroke mortality than the 
diastolic BP in Framingham heart study [13]. Similarly, the prospective population-
based Copenhagen city heart study demonstrated systolic BP to be a better predictor 
of stroke than the diastolic BP [14]. The Asia Pacific Cohort Studies Collaboration 
(APCSC), an extension of the Eastern Stroke and Coronary Heart Disease 
Collaborative project, which analyzed 37 cohort studies of 425,325 patients in the 
Asia Pacific region, demonstrated a continuous, log-linear association between 
systolic BP and risk of stroke down to the levels of 115 mm Hg of systolic BP. In 
the age groups of <60, 60–69, and >70 years, a 10 mm Hg lower systolic BP was 
associated with 54%, 36% and 25% lower risk of stroke respectively [15]. In a meta-
analysis of 61 prospective studies by the Prospective Study Collaboration (PSC), it 
was demonstrated that there was more than a twofold decrease in stroke mortality 
with each 20 mm Hg of decrease in systolic BP for patients aged 40–69 years; and 
throughout middle and old age, usual BP is directly and strongly related to vascular 
(and overall) mortality, without any evidence of a threshold down to at least 115 mm 
Hg of systolic BP and 75 mm Hg of diastolic BP [16].
Age is an important cofactor in the relationship between hypertension and 
stroke. The direct relation between elevated BP and stroke risk is weaker in older 
aged populations than in middle-aged individuals. The APCSC observed a lower 
percentage reduction in stroke risk with similar reduction in systolic BP with 
increasing age [15]. A similar trend was observed in the PSC study [16]. Although 
there is a less robust association between hypertension and stroke risk in older 
populations, lowering BP in this population is still beneficial owing to the higher 
incidence of stroke and higher morbidity/mortality rates in this population [17].
Racial and ethnic disparities in the relationship between elevated BP and stroke 
have been reported from several observational studies from the United States. The 
Baltimore-Washington Cooperative Young Stroke Study, demonstrated a positive 
relationship between hypertension and the risk of ischemic stroke in whites and 
blacks for both sexes. In this study, age-adjusted odds ratios and 95% confidence 
interval for ischemic stroke with a history of hypertension in white males, white 
females, black males, and black females were 1.6 (0.7–3.2), 2.5 (1.1–5.9), 3.8 (1.8–7.9), 
and 4.2 (2.4–7.5), respectively [18]. Similarly, the Northern Manhattan Stroke 
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Study showed higher odds ratios for hypertension and ischemic stroke in blacks as 
compared to whites and hispanics (OR 2.0 vs. 1.8, 1.2 respectively) [19]. A similar 
increase in systolic BP is associated with a nearly three times higher risk of stroke risk 
in blacks as compared to whites [20].
2.1.2 Hypertension related stroke and its pathophysiological mechanisms
Although arterial hypertension is a major risk factor for both stroke and myocar-
dial infarction, stroke is much more closely related to elevated levels of BP per se. It 
has been suggested that a sustained reduction in systolic blood pressure of 10 mm 
Hg would reduce stroke risk by 56%, but reduce the risk of myocardial infarction 
by only 37% [11]. This difference is largely attributed to the possibility that elevated 
levels of blood pressure are directly responsible for strokes occurring due to small 
vessel disease, but is only indirectly related to the development of atherosclerotic 
changes. Atherosclerosis in the arterial tree is usually focal and is usually seen at the 
branching points of the arteries or where arteries take a bend. It is likely that the 
effects of hypertension on atherosclerosis are not per se due to pressure energy, but 
are more likely related to the transmission of kinetic energy to the arterial wall at 
sites of flow disturbance, thus leading to the formation of atherosclerotic plaques at 
the areas of low shear stress [21].
Strokes due to small vessel disease, in contrast, are directly caused by elevated 
blood pressure. For this reason, these tend to occur in a particular distribution at 
the base of the brain, where short, straight arteries with limited branches result in 
direct transmission of high blood pressure directly from the large arteries to the 
smaller resistance vessels, with resultant damage to the walls of the arterioles. This 
results in the pathological changes of hyaline degeneration and fibrinoid necrosis, 
with consequent lacunar infarctions where the arterioles occlude and hypertensive 
intracerebral hemorrhages where they rupture. These pathophysiological changes 
account for the fact that true lacunar infarctions and intracerebral hemorrhages are 
particularly distributed in the areas of basal ganglia, internal capsule, thalamus, 
cerebellum, and brainstem [22].
Hypertension can indirectly contribute to the development of stroke as it is an 
important etiological factor for atrial fibrillation and for acute myocardial infarc-
tion and left ventricular clot formation; with attendant risk of cardioembolic stroke.
There are many theories related to the pathophysiological mechanisms of hyper-
tension related brain dysfunction. Central to these theories are the mechanisms 
related to impaired cerebrovascular auto-regulation in hypertension and the chronic 
maladaptive changes in the structure of the cerebral vasculature in hypertensive 
patients.
Cerebrovascular autoregulation is the process by which cerebral vasculature 
regulates intracranial blood flow, so that a steady perfusion is maintained to meet 
the metabolic needs of the brain tissue across a range of systemic blood pressures. 
This control is achieved by the ability of the cerebral arterioles to compensate for 
a decrease in cerebral perfusion pressure by vasodilatation, and also, to protect 
the brain against increased perfusion pressure by vasoconstriction, thus keeping 
the cerebral blood flow constant. This complex process is regulated by interplay 
between sympathetic nervous system, brain carbon dioxide and other metabolites, 
and neurovascular coupling. In normotensive individuals, this response occurs 
over a range of approximately 60–160 mm Hg systolic BP; but, in patients with 
hypertension, this range may be shifted to higher pressures [23, 24]. This upward 
shift in the limits of pressure autoregulation, make hypertensive patients especially 
susceptible to episodes of hypotension, which plays a role in the development of 
white matter changes. Also, elderly hypertensive patients often have impaired 
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cerebrovascular autoregulation which contributes to the development of stroke, 
cognitive dysfunction and vascular dementia. Impaired autoregulation increases 
the transmission of elevated pressures to cerebral capillaries resulting in increased 
permeability of blood brain barrier (BBB), parenchymal edema, inflammation 
neuronal degeneration that is commonly seen in patients with vascular cognitive 
dysfunction [25]. Chronic hypertension has been reported to promote arteriolar 
and capillary rarefaction, especially in the deep hemispherical white matter and 
basal ganglia [26]. This is associated with infiltration of perivascular macrophages, 
endothelial dysfunction, increased oxidative stress, and impaired functional 
hyperemia [27]. These changes promote the development of lacunar infarcts, white 
matter hyper-intensities, microinfarcts, and microbleeds [28].
Chronic elevation of intraluminal pressure stimulates the growth of smooth 
muscle cells and increases media thickness in resistance arteries, resulting in hyper-
trophic remodeling, thus causing an elevated vascular resistance. There may also be 
eutrophic remodeling, characterized by inward remodeling with rearrangement of 
the vessel wall components that leads to a reduction in lumen diameter and elevated 
vascular resistance. Hypertension may also result in narrowing of the intermediate 
and small vessels due to lipo-hyalinosis and micro-atherosclerosis. Also, chronically 
elevated BP promotes hyaline degeneration, fibrinoid degeneration and formation 
of microaneurysms in small vessels of the cerebral vasculature. These small vessel 
alterations predispose these patients to the development of ischemic and hemor-
rhagic complications [29].
Hypertension promotes atherosclerosis in large extracranial and intracranial 
arteries, which predispose to the development of atherothrombotic infarctions. 
The most frequent sites of atherosclerosis are common carotid artery bifurcation, 
origin and intra-cavernous part of internal carotid artery, first segment of middle 
cerebral artery, origin and distal part of vertebral artery, and middle portion of 
basilar artery [29]. These atherosclerotic plaques are usually progressive and lead 
to ischemic strokes by thrombotic occlusion of the narrowed lumen or, more often, 
by their acute rupture, which causes atheroembolism resulting in occlusion of 
distal intracranial vessels [29]. Major mechanisms of hypertension related cerebral 
dysfunction are summarized in Table 1.
2.1.3 Blood pressure management for primary and secondary stroke prevention
2.1.3.1 Hypertension control for primary stroke prevention
The relation between BP and stroke risk is direct, strong, linear, and etiologically 
predictive. Thus, within the usual BP ranges, including non-hypertensive ones, 
the higher levels of BP are associated with increased risk of stroke [16]. Non-
hypertensive individuals with slight elevations of BP (prehypertension, defined as 
systolic BP of 120–139 mm Hg and/or diastolic BP of 80–89 mm Hg) derive benefit 
Impairment of cerebral autoregulation
Increased permeability of blood brain barrier
Endothelial dysfunction, oxidative stress, impaired functional hyperemia
Small vessel changes: remodeling, increased vascular resistance, lipo-hyalinosis, micro-atherosclerosis, micro 
aneurysms, lacunar infarcts
Large vessel changes: atherosclerosis with atherothrombotic, atheroembolic infarctions
Table 1. 
Potential mechanisms of hypertension related cerebral dysfunction.
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from lifestyle changes with or without pharmacological therapies. A meta-analysis 
with 70,664 prehypertensive individuals from 16 trials demonstrated a robust 22% 
reduction in the stroke risk in individuals randomized to pharmacological therapy 
arm as compared to the placebo arm. In hypertensive patients, lifestyle approaches 
combined with adequate BP treatment and control produced a 35–40% decrease in 
the stroke risk [30, 31].
Practical strategies for hypertension management for primary stroke preven-
tion, on the basis of recommendations made by the American Heart Association 
(AHA)/American Stroke Association (ASA) [32, 33], and European Society of 
Cardiology (ESC)/European Society of Hypertension (ESH) [34] include:
1. Regular screening for hypertension and management of raised BP using  
lifestyle modifications and pharmacological therapies are recommended.
2. According to European guidelines the target BP in those with hypertension 
should be <140/90 mm Hg, whereas, the recent American guidelines recom-
mend a BP goal to lower levels of <130/80 mm Hg, even in very elderly.
3. Successful attainment of BP goal is emphasized over the administration of a 
particular anti-hypertensive agent.
4. Individualized BP treatment is recommended, based on particular patient 
characteristics and tolerance to medications.
5. Self-monitoring of BP is recommended to help in adequate BP control.
2.1.3.2 Hypertension management in acute ischemic stroke
Management of elevated BP in acute ischemic stroke (AIS) has been a matter of 
considerable debate. AIS is usually associated with islands of infarcted tissue with 
surrounding areas of potentially salvageable tissue, referred to as ischemic penum-
bra. Moreover, the infarcted tissue is characterized by loss of autoregulation with 
increased vessel permeability [35]. Hence an over aggressive approach of lowering 
BP can result in extension of infarction and worsening of neurological dysfunction. 
On the other hand, if the elevated BP is not lowered sufficiently, there is risk of 
excessive cerebral edema and hemorrhagic transformation of the infarcted tissue. 
Furthermore, as the cerebrovascular auto regulatory response is set at a higher level 
in chronic hypertensive patients, these individuals are at risk of impaired cerebral 
perfusion if BP is lowered very aggressively.
Practical strategies for management of hypertension in AIS, based on recom-
mendations of AHA/ASA [36], and European stroke organization (ESO) [37] 
include:
1. In patients with AIS who are not eligible for systemic thrombolysis or mechani-
cal thrombectomy and who have a BP > 220/120 mm Hg, guarded BP reduction 
(<15% systolic BP reduction over 24 h) is reasonable and is likely to be safe. No 
recommendations are made regarding the use of a specific anti-hypertensive 
agent to achieve this goal.
2. In hospitalized patients with AIS and blood pressure < 220/110 mm Hg not 
treated with intravenous thrombolysis or mechanical thrombectomy, there is 
suggestion against the routine use of blood pressure lowering agents at least in 
first 24 h following symptom onset, unless this is necessary for specific comorbid 
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conditions like acute aortic dissection, acute myocardial infarction, pulmonary 
edema, hypertensive encephalopathy and acute renal failure.
3. In patients with AIS undergoing treatment with intravenous thrombolysis 
(with or without mechanical thrombectomy) it is suggested that BP is main-
tained below 185/110 mm Hg before bolus and below 180/105 mm Hg after 
bolus, and for 24 h after alteplase infusion.
4. In patients with AIS undergoing treatment with intravenous thrombolysis 
(with or without mechanical thrombectomy), there is suggestion against 
lowering systolic blood pressure to a target of 130–140 mm Hg compared to 
<180 mm Hg during the first 72 h following of symptom onset.
5. Initiating or continuing anti-hypertensive agents during hospitalization for 
AIS, if BP > 140/90 mm Hg: BP lowering is generally safe in AIS if patient is 
medically and neurologically stable, and there are no contraindications for 
BP lowering. The time window for administration of such therapies is usually 
2–3 days after the symptom onset.
Drug options to treat hypertension in patients with AIS who are planned for 
emergency reperfusion therapy are shown in Table 2.
2.1.3.3 Hypertension management in acute hemorrhagic stroke
Observational studies have suggested that BP is often markedly elevated in 
the acute phase of hemorrhagic stroke, significantly higher than that seen after 
AIS [38]. High levels of BP in acute hemorrhagic stroke are often associated with 
hematoma expansion and poor clinical outcomes [39]. Simultaneously, there have 
been suggestions that high BP may be necessary to maintain adequate cerebral 
perfusion after intracranial hemorrhage, and that aggressively lowering it may 
be deleterious. These concerns are however, opposed by the evidence suggesting 
that adequate cerebral perfusion is maintained after acute BP reduction in patients 
with hemorrhagic stroke [40, 41]. However, results of the two largest randomized 
clinical trials (INTERACT2, ATACH-2) of intensive BP lowering early after intra-
cranial hemorrhage have renewed this uncertainty [42, 43]. Meta-analyses of these 
trials and many other smaller studies have shown that early intensive BP reduc-
tion after hemorrhagic stroke is safe, but without mortality benefit or significant 
functional improvement [44–47]. In contrast, a recent meta-analysis of the two 
largest trials demonstrated a direct linear relation between the level of systolic BP 
Labetalol: 10–20 mg intra-venous over 1–2 min, may be repeated once; or
Nicardipine: 5 mg/h intra-venous, dose may be up-titrated by 2.5 mg/h in every 5–15 min to a maximum of 
15 mg/h; when desired BP levels is obtained, adjust the dose to maintain proper BP levels; or
Clevidipine: 1–2 mg/h intra-venous, up-titrate by doubling the dose in every 2–5 min until desired BP level is 
obtained; maximum dose 21 mg/h
Other agents like enalaprilat, hydralazine may also be useful
If BP is not controlled or diastolic BP > 140 mm Hg, consider intravenous nitroprusside (may increase 
intracranial pressure).
Table 2. 
Drugs for acute management of elevated blood pressures in patients of acute ischemic stroke who are planned 
for emergency reperfusion therapy [36, 37].
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achieved during the first 24 h of hemorrhagic stroke and the functional status. The 
improvements in the functional status were noted for systolic BP levels of as low as 
120–130 mm Hg [48]. These studies however excluded patients with severe, large 
hematomas and hence caution is warranted in too aggressive lowering of BP in such 
patients as it might predispose to harmful consequences [49].
Practical strategies for BP control in patients with acute hemorrhagic stroke 
based on recent AHA/ASA [50], and ESO [37] guidelines include:
1. If initial systolic BP is >220 mm Hg, it is reasonable to administer continuous 
intravenous BP lowering therapy to achieve an initial reduction of about 15%. 
Choice of drugs is similar to that used in AIS (Table 2).
2. In patients with initial systolic BP of 150–220 mm Hg, American guidelines 
suggest a target goal of 140–150 mm Hg of systolic BP [50], however, the  
recent ESO guidelines [37] recommend even more aggressive lowering of 
systolic BP to less than 140 mm Hg (but to keep it above 110 mm Hg) to reduce 
hepatoma expansion.
3. Control of blood pressure variability may be helpful in improving the  
outcomes [51].
4. After hemorrhagic stroke, the optimal timing for initiation of antihyperten-
sive therapies for secondary stroke prevention has not been well established. 
It may be reasonable to start such treatment when the patient is medically and 
neurologically stable. The target BP goal for secondary stroke prevention is 
<130/80 mm Hg [50].
2.1.3.4 Hypertension management for secondary stroke prevention
About a quarter of strokes are recurrent, the annual risk of recurrence is nearly 
4% and the mortality rate after a recurrent stroke is 41% [33, 34]. A large proportion 
of strokes can be prevented by adequate BP control, regular physical activity, healthy 
dietary habits and cessation of smoking. In fact, the INTERSTROKE study demon-
strated that these 5 factors—hypertension, imbalanced diet, lack of adequate physical 
activity, abdominal obesity and smoking—were responsible for 82% and 90% of the 
population attributable risk (PAR) for ischemic and hemorrhagic stroke respectively 
[6]. Also, the Global Burden of Disease Study suggested that nearly 90% of the global 
stroke burden was attributable to the modifiable risk factors [52]. A modeling study 
has shown that targeting multiple modifiable risk factors of stroke has additive benefits 
in secondary prevention of stroke. According to this study, aspirin, anti-hypertensive 
therapies and statins, along with dietary modification and adequate exercise, can lead 
to an 80% cumulative risk reduction in the incidence of recurrent vascular events [53].
Practical strategies for BP control for secondary recent AHA/ASA guidelines 
[54] include:
1. In hypertensive patients who suffer a stroke or transient ischemic attack (TIA), 
an office BP goal of <130/80 mm Hg is recommended for most patients to  
reduce the risk of recurrent stroke and vascular events.
2. In individuals with no history of hypertension who experience a stroke or TIA 
and have an average office BP of ≥130/80 mm Hg, antihypertensive drug treat-
ment can be beneficial to decrease the risk of recurrent stroke, intracranial 
hemorrhage, and other vascular events.
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3. A thiazide diuretic, angiotensin converting enzyme (ACE) inhibitor or 
angiotensin receptor blocker (ARB) may be useful, however, other classes of 
BP lowering therapy can be used to achieve the target BP goals (e.g., calcium 
channel blocker, newer generation beta blocker).
4. Individualized drug treatments that take into account patient comorbidities, 
pharmacological class of the drug, and patient preferences are recommended 
to maximize the drug efficacy.
2.2 Hypertension and dementia
2.2.1 Hypertension as a risk factor for cognitive dysfunction and dementia
Dementia is characterized by a progressive and often irreversible decline of 
cognitive function which is most commonly seen in older adults. It is one of the most 
common neurological diseases, nearly affecting 30–40 million people worldwide. 
The number of people with dementia is estimated to triple by 2050, largely driven 
by the aging of the population, demographic shifts, and lack of disease-modifying 
therapies [55]. Alzheimer disease (AD) and cerebrovascular diseases are the major 
causes of cognitive dysfunction, accounting for nearly 80% of the cases and often 
have a mixture of both the pathologies [55]. Although the majority of dementias 
including AD are primarily considered as neuro-degenerative diseases of unknown 
cause, recent studies have shown that cerebrovascular disease and microscopic 
vascular lesions are often found in patients affected by these conditions [56].
The term vascular cognitive impairment (VCI) refers to the entire spectrum of 
cognitive abnormalities caused by vascular etiologies, whereas the term vascular 
dementia is used for cases with more profound vascular cognitive deficits which 
negatively affect the daily functioning of an individual [57].
Among the various vascular risk factors, systemic hypertension is a major 
factor contributing to cognitive impairment [57]. It has been been associated with 
decreased abstract reasoning, reduced mental processing speed, and, less com-
monly, memory deficits [58]. Although dementia due to AD and vascular demen-
tia have classically been considered as separate entities, recent evidence indicates 
that the two conditions are frequently coexistent [59, 60]. In nearly 40–50% of 
cases with a clinical diagnosis of AD, the pathological hallmarks of AD (amyloid 
plaques and the neurofibrillary tangles), are associated with micro-cerebrovascu-
lar and macro-cerebrovascular lesions [61]. Moreover, ischemic lesions markedly 
elevate the effect of AD pathology on cognitive function [62, 63]. Also, traditional 
cardiovascular risk factors have been suggested to have a role in the development 
of AD [64], and some estimates suggest that risk factor modification, especially 
the treatment of hypertension, could decrease the incidence of clinically diag-
nosed AD by up-to 30% [65].
2.2.2 Mechanisms of hypertension related cognitive dysfunction
Hypertension-related cognitive dysfunction occurs as a result of complex inter-
play between functional alterations and structural changes seen in the brain paren-
chyma and the cerebral vasculature, many of which have been discussed previously 
in Section 2.1.2. Briefly, these changes include increased cerebrovascular resistance, 
reduced vasomotor reactivity, decreased cerebral blood flow, vascular remodeling, 
lacunar infarcts, white matter lesions, micro bleeds, enlarged perivascular spaces 
and cerebral atrophy [66]. These overlapping pathophysiological changes might 
account for the correlation between hypertension and stroke or vascular dementia. 
Cerebrovascular Diseases
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This relation may also hold true for other forms of dementia; like, for example the 
link between chronic hypertension and the AD has been documented, as hyperten-
sion is often associated with formation of neurofibrillary tangles and senile plaques, 
the presence of which was seen in brains of hypertensive patients even in the 
absence of clinical features of dementia [67].
2.2.3 Prevention of cognitive dysfunction by antihypertensive therapy
Hypertension is a major modifiable risk factor for cognitive dysfunction, VCI and 
AD. Robust clinical evidence has demonstrated that antihypertensive therapies, besides 
preventing major cerebrovascular events [57], also reduce the incidence and/or delay 
the progression of cognitive dysfunction [68, 69]. The Syst-Eur randomized clinical 
trial showed that, on treating 1000 hypertensive individuals with anti-hypertension 
therapies for 5 years, 19 cases of dementia could be prevented [70]. Similarly, the 
PROGRESS trial observed that therapy with a perindopril (a long-acting ACE inhibi-
tor), and indapamide (a thiazide-like diuretic), was associated with reduced risks 
of cognitive dysfunction and dementia on a mean follow-up of 3.9 years [71]. Also, 
various clinical and experimental studies have suggested that antihypertensive drugs, 
including ACE inhibitors, angiotensin receptor blockers (ARBs) and diuretics, might 
cause an improvement in the biomarkers of AD, and decrease the incidence of AD  
and/or delay its progression [72].
Interestingly, antihypertensive drug therapies might have class specific effects 
on cognitive function. Both ACE inhibitors and calcium channel blockers have 
been reported to delay the development of cognitive dysfunction [72]. However, 
results from the Canadian Study of Health and Aging suggested that hypertensive 
individuals aged ≥65 years who received treatment with calcium channel blockers 
had a more marked cognitive decline than those receiving other antihypertensive 
drugs at follow-up of 5 years [73]. These findings lend support to the hypothesis 
that the systemic and local renin-angiotensin systems may respond differently to 
different antihypertensive drugs [74]. Furthermore, calcium channel blockers may 
potentially cause an impairment of myogenic autoregulatory protective responses 
in the cerebral vasculature. Taking these factors into account, it might be suggested 
that ACE inhibitors and ARBs might be preferable to calcium channel antagonists 
for dementia prevention in hypertensive patients [75].
The subject of optimum BP targets for the prevention of dementia has generated 
considerable debate and controversy. In the SPRINT MIND trial, it was seen that in 
ambulatory hypertensive individuals, a more intensive BP control strategy (target 
systolic BP of <120 mm Hg as compared to a target of <140 mm Hg) was not associ-
ated with any significant cognitive benefits [76]. An important point to be considered 
here is that due to the adaptive rightward shift of the cerebrovascular autoregulatory 
curve in hypertension, too aggressive lowering of BP may result in cerebral hypoper-
fusion and consequential negative impact on the brain. These U-shaped associations 
between BP and cognitive function in the elderly individuals have been reported in 
many studies [77, 78]. These findings stress the importance of individualized blood 
pressure management strategies for prevention of cognitive dysfunction.
Hypertension is also a major contributor to the risk of stroke, which nearly 
doubles the risk of developing dementia. It is estimated that about one-third cases 
of dementia can be prevented by preventing the development of stroke [79]. 
Clinical studies have shown that prevention of stroke by using anticoagulation in 
atrial fibrillation and BP-lowering therapies in hypertensive patients can signifi-
cantly decrease the risk of dementia [80]. Based on these results, the World Stroke 
Organization came out with a manifesto stressing the need for a joint strategy for 
prevention of stroke and dementia [79].
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3. Conclusions
Hypertension is a major global public health problem and is the major cause of 
premature death worldwide. Human brain is highly vulnerable to the deleterious 
effects of elevated blood pressures. Hypertension related cerebrovascular diseases 
include stroke, cognitive dysfunction and dementia. Elevated blood pressure levels 
are strongly, directly and linearly related to the incidence and prevalence of these 
diseases. Adequate management of hypertension can go a long way in mitigating the 
global burden of these cerebrovascular diseases.
4. Final remarks
Elevated systemic blood pressures are associated with increased risk of cere-
brovascular diseases including stroke and dementia. Good blood pressure control, 
which can be achieved easily in majority of the patients, is necessary for prevention 
of these cerebrovascular diseases.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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